Endocrine Therapy for Breast Cancer

Recruiting at 6 trial locations

Overseen By Anita Mamtani, MD

Age: 18+

Sex: Female

Trial Phase: Phase 2

Sponsor: Memorial Sloan Kettering Cancer Center

Disqualifiers: Prior breast cancer, Advanced regional disease, others

Stay on Your Current Meds You can continue your current medications while participating

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

176 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).

Who Is on the Research Team?

Anita SKCCSC(P Mamtani, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I am a postmenopausal woman over 50 with ILC and am able and willing to have breast-conserving surgery.

* Written informed consent by participant or legally authorized representative

My tumor is estrogen receptor positive (ER+).

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Neoadjuvant Endocrine Therapy

Participants receive neoadjuvant endocrine therapy before surgery to evaluate its effectiveness in reducing positive surgical margins

up to 3 months

Surgery

Participants undergo breast-conserving surgery to remove cancerous tissue

Follow-up

Participants are monitored for safety and effectiveness after surgery

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Neoadjuvant Endocrine Therapy

How Is the Trial Designed?

Group I: Participants with ER+/HER2- Breast Cancer Experimental Treatment 1 Intervention

Participants will be postmenopausal women aged ≥50 years with biopsy-proven cT2-T3 N0-1 ILC, ER+/HER2- subtype

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+